• BevCanna Enterprises Inc is a diversified health & wellness beverage and natural products companies which deals in the manufacture and distribution of both, in-house brands, and white-label clients
• The company currently boasts over 3,000 points of distribution and online through which it retails the company’s market-leading TRACE brand, its Pure Therapy natural health products as well as its various, cannabis infused beverages.
• BevCanna’s strong execution recently saw it report 3Q2021 revenues of $1.1 million, representing a rise of over 1,000% relative to a year ago
• BevCanna Enterprises separately announced that it has been named as one of the 101 Top Food and Beverage Startups and Companies in Canada by Best Startup Canada

In 2013, Marcello Leone, CEO and Founder of BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), was suffering from a series of afflictions. He would get walking pneumonia twice a year and experience a flare up in his runners’ knee nearly every other day; it was then that Leone’s wife introduces him to TRACE, a plant based functional beverage. After trying it once, Leone never looked back (https://ibn.fm/XMfky). Over the past several years, BevCanna Enterprises, a diversified health & wellness beverage and natural products company developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients, has seen its business go from strength to strength, recently being recognized as one of the Top 101 Food and Beverage Startups and Companies in Canada with its products now available online and at over 3,000 points of regulated and traditional points of sale across the nation; Accounting for the cannabis distribution and the traditional CPG distribution. In a recent interview, Leone elaborated on how BevCanna had actively sought to differentiate their business model from others within the beverage space, “We focus on alkaline and plant-based functional beverages and nutraceuticals as well as CBD and THC infused beverages. So, we are a little bit unique in that respect as we have one of our divisions which is a CPG division and then we have our other division which is a federally licensed producer of cannabis infused beverages.” A key pillar underpinning the company’s model has been its full-service white label beverage manufacturing solution, which has seen the company partner with several iconic brands in their bid to enter the Canadian market. Offering a range of services which include, beverage processing, product development, packaging, and distribution, BevCanna’s current portfolio of brand partnerships include the likes of the United States’ leading cannabis beverage brand, Keef (cannabis-infused classic soda), the Tinley Beverage Company, Averi Health Products, Green Monké, and the Xebra Brand Ltd, among others. Simultaneously, BevCanna have also sought to further their commercial appeal – recently arriving at an agreement with UNFI Canada  as well as the wholesale distributor Koyo Foods Inc. Seeing the company’s wholly owned subsidiary Naturo Group’s TRACE line of products to retailers, In a deal which will result in significant expansion of the companies over 3,000 points of retail distribution across the country. BevCanna Enterprises’ strong execution and expanding white-label brand portfolio has been reflected in their recent financial results, with the company reporting third quarter 2021 results which saw their revenues rise by upwards of 1,000 percent to $1.1 million. At the time BevCanna Chief Financial Officer, John Campbell remarked, “As we closed out the third quarter, we delivered impressive revenue growth of more than 1,000%, achieving $1.1 million in sales, compared to $94,000 in the year-ago quarter… Our third-quarter results are further evidence of the company’s continued execution and the impact that our brands are having on the market.” (https://ibn.fm/nOazX). For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demand
• The launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achieved
• BayMedica acquisition, other key achievements in 2021, are positioning the company as a leading supplier of rare cannabinoids in the health and wellness sector

A leader in the research, development, manufacturing and commercialization of rare cannabinoids, InMed Pharmaceuticals (NASDAQ: INM) has begun the new year from a more prominent position in the market, following key acquisitions and milestones attained in 2021 and the launch of a new product, cannabicitran (“CBT”). The company is uniquely positioned to leverage the worldwide growing awareness of the potential benefits of cannabinoids and a rising demand for rare cannabinoids in particular (https://ibn.fm/4WTrf). According to Grand View Research, the rare cannabinoid retail market is anticipated to reach $26 billion by 2028 (https://ibn.fm/QSfbr). Commercial scale access to rare cannabinoids will enable consumer brands and product manufacturers to deliver differentiated products as well as to enhance existing products for health and wellness consumers. With the launch of business-to-business sales of CBT in the health and wellness sector, InMed has further expanded its portfolio and its presence in the growing rare cannabinoid market. CBT is the first of several new products InMed is planning to launch in the first half of 2022 in response to growing demand. “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cannabinoids in these sectors,” stated Shane Johnson, SVP and General Manager of InMed’s subsidiary and recent acquisition BayMedica. BayMedica has already received initial purchase orders and begun commercial sales of CBT, the second rare cannabinoid it launched in the health and wellness sector after cannabichromene (“CBC”). Additionally, the company has initiated commercial scale production of cannabidivarin (“CBDV”) and plans to launch tetrahydrocannabivarin (“THCV”) production shortly after, expecting to manufacture over 100kg of both cannabinoids in the coming months. The CBT launch further demonstrates InMed’s ability to produce rare cannabinoids at commercial scale, an achievement not many companies have been able to attain, according to Johnson. “We are pleased with initial demand and we expect to grow sales over the coming quarters as we continue to expand our product portfolio of rare cannabinoids,” he added. The company is all but guaranteed to attain higher sales, given its ability to scale up based on demand and its flexibility in marketing approaches, paired with a stern commitment to ensuring quality, consistency and purity of product through proprietary processes. Moreover, the key acquisition of BayMedica in October 2021 gave InMed access to proven proprietary synthetic manufacturing methods that can be successfully utilized to custom formulate cannabinoids for multiple health and wellness applications, including nutraceuticals, supplements, cosmetics and animal health products. Other key milestones reached in 2021, as per a recent letter to shareholders from InMed President and CEO Eric A. Adams, include (https://ibn.fm/igZHd):

• Maximizing production yield of pharma-grade manufacturing process, IntegraSyn(TM) – An industry-leading yield of 5g/L was achieved in June 2021, with plans to further optimize the platform for large-scale, pharmaceutical-grade production of rare cannabinoids.
• Furthering INM-755 program for Epidermolysis Bullosa (“EB”) treatment – A Phase 2 efficacy trial was initiated in September 2021, the first time that cannabinol (“CBN”) has reached a Phase 2 clinical trial as a therapeutic option to treat a disease.
• Advancing INM-088 program for glaucoma treatment – Getting one step closer to launching human clinical trials, the InMed team has conducted several preclinical studies to validate the use of CBN for the treatment of glaucoma, a condition that affects about 80 million people worldwide.
• Conducting promising research into the use of a rare cannabinoid for neurodegenerative diseases – In October 2021, InMed filed an international patent application for the use of a rare cannabinoid, whose name was not disclosed, as potential treatment for various neurodegenerative diseases including Parkinson’s, Alzheimer’s, Huntington’s and others.

For 2022, InMed expects to build on the successes achieved in 2021, especially the acquisition and integration of BayMedica, to secure consistent revenue growth and further advance its pharmaceutical drug development programs, transitioning to become a leading B2B supplier of rare cannabinoids in the consumer health and wellness market. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• SRAX, premier provider of investor intelligence and communications platform, announces the quantity of stock bought-back in Q4 and dividend payment
• $800K worth of shares was repurchased in Q4 as part of company’s $10M stock buy-back program; dividend for common stockholders paid in preferred shares
• SRAX’s corporate action comes amid period of solid growth and robust financial performance

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, announces the number of shares repurchased in the fourth quarter of 2021 and the first payment for the previously issued dividend (https://ibn.fm/lrN26). The repurchase initiative is in line with the company’s $10M stock buy-back program and the intended dividend payment to the holders of SRAX common stock, both of which were announced in Q3 2021. The company bought back approximately 155,000 of common shares during the last quarter of 2021. At an average price of $5.12 per share, this repurchases initiative amounts to approximately $800K. The dividend for the holders of SRAX common stock was paid in the form of preferred shares, which hold shares from SRAX clients that are periodically sold with proceeds to be paid within 30 days following the end of each quarter. The company announced that it sold approximately $380K of this type of shares during the last quarter, which entitled each holder to a cash payment of $0.01 per share due by January 30th, 2022. SRAX has seen its financial performance growing stronger and stronger over the past year. With its proprietary SaaS platform Sequire, SRAX solves some of the most critical problems for public companies and investors alike. The former strives to better communicate with their shareholders and the broader investment community, while the latter seek transparency and actionable insights to uncover compelling growth opportunities in today’s cluttered digital environment. The company offers a host of tools that public companies need to get noticed by the investment community and thrive. As a big data analytics platform, Sequire allows public companies to track their investors’ buying and selling behavior and use this information to engage their investor base across different marketing channels. With Sequire, companies have access to key data to understand the market activity, such as market maker behavior, buying/selling trends, new shareholders, and breakdowns of shareholder positions. SRAX is also a renowned organizer of investor conferences–arguably the best known and most respected conference provider focused on the small and micro-cap markets. Committed to delivering value to its shareholders and clients alike, the company continues to make strides when it comes to positioning itself as a go-to data provider for the small and mid-cap market. “We continue to optimize our cap table and return value to our shareholders,” said Christopher Miglino, Founder and CEO of SRAX. “This quarter we re-filed our already existing shelf. This allowed us to eliminate our At the Market filing (‘ATM’) and the costs associated with it. We will continue to look for opportunities to reward our shareholders,” concluded Miglino. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Plant-based food supply chain vertical innovator Eat Well Investment Group Inc. is dedicated to building a supply of more nutritious and tasty foods for international consumers throughout North American markets
• Majority-owned subsidiary Amara toddler organic food line recently announced it has expanded its presence in H-E-B’s stores throughout Texas since its launch with the retailer last year, including two new plant-based flavors
• Amara is also being distributed through other big box and e-commerce giants such as Walmart, Amazon and Loblaws
• Eat Well expects its revenues to grow to $100 million by year’s end

The rising profile of baby food brand Amara Organic Foods has been a boon to plant-based foods investment company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF), which acquired 51 percent ownership of the company in October with an option to obtain up to 80 percent if it wishes. Amara is being distributed through e-commerce giants Amazon and Walmart, and through big-box retailers such as Walmart, Whole Foods, Sprouts Farmer’s Market and, in Canada, Loblaws Inc. In June Amara launched in independently owned food retailer HEB Grocery Company, LP (known as H-E-B), which serves Texas and Mexico, and has since expanded to 200 of H-E-B’s stores with new baby food flavors tropical mango and peas, corn and carrots (https://ibn.fm/YbapW). During the course of 2021, Amara enjoyed 533 percent revenue growth and was named Amazon’s top new release (https://ibn.fm/lvqck). “We’re thrilled to be expanding our retail shelf footprint with one of our key retailers, H-E-B. It’s a true testament to Amara’s strong growth in the category and the changing customer,” Amara founder and CEO Jessica Sturzenegger stated in the Feb. 1 news release. “Customers are increasingly thinking about the food they eat and Amara’s truly the only baby food that can bring all the benefits of fresh with the convenience of shelf stable.” Parent company Eat Well Investment Group is dedicated to investing in the entire plant-based food supply chain from seed to market. Its vertical integration of agribusiness, foodtech, and CPG brands has the ultimate goal of providing more nutritious and more exciting foods to consumers on an international scale — doing so through a blend of natural and traditional-big box retailers to reach families in a variety of lifestyle communities. Another Eat Well acquisition, Sapientia, launched plant-based twisted curls snacks as the company’s first commercial product shortly before Christmas (https://ibn.fm/A6gSg). Sapientia founder and President Dr. Eugenio Bortone previously invented the Twisted Cheetos, which netted approximately $200 million in retail sales during its first calendar year and Sapientia has high hopes for its twisted curls. The snack is being distributed through 350 Federated Co-operatives Limited Ltd. (“FCL”) stores under the COOP Pure Brand. “There is nothing in the category that has this much protein and fibre and still tastes like a regular salty snack and made locally here in Western Canada,” FCL’s Head of Store Brands Sav Bellissimo stated. Eat Well also has 100 percent ownership of Belle Pulses Ltd., one of Canada’s top pulse processors. Belle Pulses netted more than $60 million in sales in 2020. Eat Well expects its revenues to grow to $100 million by the end of this year. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• Tens of millions of Americans live in areas where mental health providers are scarce
• Delic is working on making psychedelic-based treatments more accessible and affordable
• In 2021, the company acquired Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers, becoming the owner and operator of the largest chain of wellness clinics administering ketamine treatments in the U.S.

A May 2021 CNBC article exploring the cost and accessibility of mental health care in the United States noted that the number of Americans experiencing depression and anxiety had increased – a total of 42% of U.S. adults had reported symptoms, up from 11% in preceding years – due to the COVID-19 pandemic, among other factors (https://ibn.fm/1HcId). “Spending on mental health treatment and services reached $225 billion… That number, which is up 52% since 2009, includes spending on things like therapy and prescription medication as well as stays in psychiatric or substance abuse rehabilitation facilities. It doesn’t take into account indirect costs, such as lower workforce participation rates and decreased productivity… And access to care can be prohibitively expensive,” the article notes. While overall access and coverage for mental health and substance abuse treatments have improved over the years, the article discusses a number of other factors that still make it difficult for patients to get affordable care. “Mental health and substance use treatment centers and clinics, for instance, tend to be concentrated in urban areas. Rural parts of the country tend to lack access to more specialized treatment options… In fact, more than 112 million Americans live in areas where mental health providers are scarce,” the article adds. For Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, the prohibitive costs and limited access to mental health care are primary motivators. Accordingly, the company is working to make psychedelic-based treatments more accessible and affordable by leveraging its growing psychedelic wellness clinics in the United States. In 2021, Delic completed the acquisitions of Ketamine Infusion Centers (“KIC”), a limited liability corporation that owns and operates a ketamine infusion treatment clinic in Phoenix, Arizona, and Ketamine Wellness Centers (“KWC”), the largest national chain of wellness clinics in the United States (https://ibn.fm/iNRwR). These acquisitions brought the number of operational wellness clinics under the Delic umbrella to 12, cementing the company’s position as the owner and operator of the largest, most profitable chain of mental health clinics in the United States. According to Delic, these clinics are strategically located in secondary cities to improve accessibility and reach as well as help the greatest number of patients. Still, the company plans to serve even more people with the opening of 14 additional clinics over the next 18 months as well as expansion into localities where access to mental health treatments is limited (https://ibn.fm/3owEb). The U.S., Delic Co-founder and CEO Matt Stang notes, is home to 51.5 million people who have experienced a mental health condition, and the pandemic has only exacerbated the crisis. Furthermore, the company is seeing strong demand for alternatives to current treatments with lasting outcomes and fewer side effects and has, in fact, released the findings of a commissioned study investigating this very fact. The study, conducted on its behalf by The Harris Poll, shows that a large number of Americans who suffer from anxiety/depression/PTSD believe that psychedelic medicine such as ketamine, psilocybin, and MDMA should be availed to patients with treatment-resistant anxiety, depression, or PTSD. In addition, significant percentages of those polled would be open to pursuing treatment using psychedelic medicine if they were individually proven more effective than prescription drugs with fewer side effects (https://ibn.fm/pXXls). “At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S. We see a strong outlook for Delic with the rollout of 14 additional clinics and an expansion into communities where access to these life-changing treatments is very limited. Delic is well-positioned for growth and profitability in 2022 and beyond,” concluded Stang. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• InnerScope Hearing Technologies revealed that they had retained CPA firm, PKC LLP to perform an independent audit of the company’s 2019, 2020, and 1Q-3Q 2021 results
• The audited results will be submitted to the SEC and FINRA to establish InnerScope as an SEC fully reporting company
• InnerScope has recently acquired HearingAssist, a leading direct-to-consumer hearing aid vendor as well as iHear Medical, with the latter providing the company with access to over 40 patents along with an FDA-registered manufacturing and R&D facility

InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributer/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), has revealed that it has appointed the audit services of CPA firm Paris, Kreit & Chiu LLP (“PKC LLP”) to perform an independent audit of the Company’s 2019, 2020, and Q1-Q3 2021 financial statements (https://ibn.fm/cmFwr). InnerScope also seized on the occasion to announce that the company intended to file a Form-10 or S-1 to become an SEC fully reporting company once the audit was complete and submitted to the SEC, FINRA, and other relevant agencies. Matthew Moore, President, and CEO of InnerScope commented: “InnerScope is pleased to announce the Company has formally retained CPA firm Paris, Kreit & Chiu LLP to conduct an independent audit of our 2019, 2020 and Q1-Q3 2021 financial statements. PKC LLP is a public accounting firm with offices worldwide and possesses significant experience in auditing public companies.” InnerScope recently reported their 3Q21 earnings, which coincided with the company raising $300 thousand in restricted equity – with the proceeds used to redeem outstanding convertible notes and finance ongoing marketing efforts for the company. The company also used the funds to finance the closing costs for their acquisition of HearingAssist, a long-established leader in the direct-to-consumer hearing aid market and Walmart’s largest hearing aid supplier, which was acquired for a gross consideration of $10 million, with the express intent to create a “powerful disruptive company in the global hearing device market.” At the time of acquisition, Matthew Moore, President and CEO of InnerScope, stated, “Today is a tremendous milestone for InnerScope. I’m delighted to welcome the HearingAssist team, who share our passion for providing convenient and affordable hearing products for the tens of millions of Americans who suffer from hearing loss. The HearingAssist acquisition is another meaningful step in advancing our strategy to grow as a leader and innovator in the direct-to-consumer hearing aid market.” Together with the acquisition of iHear Medical Inc., a DTC cloud-based hearing solutions provider giving InnerScope access to over 40 patents along with an FDA-registered manufacturing and R&D facility, and partnership with Atlazo Inc., a semiconductor innovator for next-generation AI smart devices, InnerScope has sought to establish a commanding position within the direct-to-consumer hearing solutions market through the sale of advanced hearing products through Walmart and other major retailers. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website at www.iHeardirect.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

On March 22-23rd, 2022, the FinovateEurope is being held in London, England. Organizations, financial institutions, fintech industry leaders, and finance influencers are invited to attend FinovateEurope 2022. Global fintech influencers and thought leaders will share valuable insights and strategies on the future of digital finance. Finovate offers a robust platform for the fintech fraternity for the last 10 years where they can connect with industry stalwarts as well as peers and derive ideas for the success of their business strategies. The event will be attended by 1000+ senior attendees, with over 50% from financial institutions, 50+ demoers, 70+ insightful speakers, a visionary audience and breadth of insights that you will experience at Finovate. After a series of remote events, FinovateEurope marks the return of the physical financial conference in London. The pandemic has completely altered the functionality of financial in-person events and intensified the use of digital technologies. The event will feature live sessions of unique fintech strategies and valuable advice from financial experts and key influencers. The biggest advantage lies in the opportunity to make networking ties that will carve a successful path for future opportunities. FinovateEurope will be digitally available to those who cannot attend the event in person. This well-curated event is accessible both as a physical and online conference globally. On March 15, 2022, attendees can participate in the FinovateEurope with live sessions and networking through ConnectMe.  Attendees can digitally access demos that will be followed by in-person demos on March 22. There will also be fireside chats, which offers a tremendous platform to make networking connections, learning, and bookmarking sessions for the in-person part of the event over March 22-23. Attendees can engage with thought leaders and establish business connections to grow their network. The FinovateEurope will be attended by influencers and experts leading the fintech revolution and industry heads who will share their insights in this 2-day global event of the financial technology industry. Connect with us at FinovateEurope to network and collaborate with the most influential people in the fintech sphere. Learn about digital transformation, customer engagement, business onboarding, open banking, and much more at FinovateEurope. To learn more about the event, please visit https://ibn.fm/13OVt.

• Friendable completed the acquisition of Artist Republik on January 4, 2022, with the Form 8-K filed with the SEC on January 10 offering an overview of that transaction
• The acquisition of Artist Republik in conjunction with Friendable’s flagship product Fan Pass Live artist platform allows for independent artists to create, perform, produce, and distribute their music without private representation
• President and CTO Dean Rositano was recently invited to join the Rolling Stone Culture Council, an invitation-only opportunity that sheds an additional positive light on the company within the music industry

One of the first reports in 2022 from Friendable (OTC: FDBL), a mobile technology and marketing company focused on identifying products, services, and brand opportunities with mass-market potential and scalability, was the successful acquisition of music production, distribution, marketing, and management platform Artist Republik on January 4. The acquisition covers all of Artist Republik’s revenue, customers, back-end processes, trademarks, internet domains and other aspects necessary to carry on the business. Friendable also entered into a consulting agreement with Artist Republik’s founder, Nick Cianfaglione. The entire Asset Purchase Agreement can be found as an Exhibit with the company’s SEC 8-K filing from December 23, 2021. Artist Republik is a subscription service designed to allow artists worldwide to take control of their music careers through networking, centralized sources, and AI-based management tools. By adding Artist Republik’s platform to Friendable’s flagship product, Fan Pass Live, the company has effectively made it possible for independent artists to manage their careers from production to performance to distribution. Artists will now be able to distribute their music on streaming platforms, receive royalties from these platforms, and create a marketplace where users can purchase beats, enhance audio production, and purchase access to curated playlists. By acquiring Artist Republik, Friendable, and the Fan Pass Live artist platform are now able to offer new skillsets and benefits to artist members (https://ibn.fm/ZrP5W), including:

• Distribution (one-time or subscription-based) – Artists can now release their music on all major streaming platforms
• Press release promotion – Submit a draft for a blog outlet post on the artist’s page
• Spotify playlisting – Submit your playlist to curators to grow artist streaming
• Elite reviews – Artists can receive feedback on their music from notable industry artists
• Custom ARTSTLNKS – A single link where artists can promote their music, merchandise, shows, and anything else they want
• Instagram promotion – Artists can grow their audience on social media by submitting their content for placed promotion
• ‘Grow with us’ features – Spotify and Soundcloud growth marketing
• Mastering – Artists can get songs mixed and/or mastered
• Sound store – Artists can purchase or sell sounds, beats, sample packs, and more
• FeaturedX – Artists book a guest feature, co-write, midi composition, or live instrumental tracking for their next single. FeaturedX is a service that requires artists to sign up to be an artist/creator on the platform
• Biz resources – Blog promotion management, playlist curation, Instagram curation, elite reviewer, and audio engineer.

The acquisition will help Friendable expand its reach into the music distribution space, a growing market worldwide. In 2020, the global music distribution services sector was valued at $911.87 million, and it is expected to grow at a CAGR of 6.2%, resulting in a market value of $1683.08 million by 2030 (https://ibn.fm/8H0Vj). A substantial part of this growth is attributed to the need for online music distribution during the pandemic – the market was able to integrate new ways of monetizing music consumption during this time, circumventing the negative impacts other markets felt. Since its launch in July 2020, Fan Pass Live has become a major player in the artist streaming world, driven by its unique business model and the unrelentless passion of brothers Robert A. Rositano, Jr. (“CEO”) and Dean Rositano (President and CTO) for artists and their music. Dean Rositano was recently selected to be a part of the Rolling Stone Culture Council – an invitation-only network of leaders on the cutting edge of what’s new in culture, community, and all things associated with the Rolling Stone brand. The move can further strengthen Friendable’s visibility and reach in the market. “Having been a touring musician in my teenage years and continuing to play music as my hobby, the Rolling Stone brand has always been something I have admired, followed, and truly coveted as an industry staple,” Dean Rositano said, describing the experience (https://ibn.fm/jaD4g). “Now to be a part of a community that identifies with this very brand, while being a founding member and CTO of Fan Pass Live, it’s kind of unbelievable to see my name associated with Rolling Stone, but it’s amazing and exciting to have such an opportunity that aligns with everything we have developed and what we are all about, supporting music artists.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• BevCanna is company developing diversified portfolio of health and wellness products for both in-house brands and white-labeled clients
• Company deploys a traditional retail and direct-to-consumer e-commerce model to offer products throughout North America
• Company actively explores opportunities within infused beverages market as CBD-infused beverages gain popularity; global market expected to reach US$2 billion by 2026

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a Canada-based diversified health and wellness beverage and natural products company developing and manufacturing a diverse portfolio of alkaline, plant-based, and cannabinoid beverages and supplements for in-house brands and white-label clients alike. Founded in 2017, BevCanna was quick to leverage a unique value that its team of established beverage experts brings to the table – deep knowledge of consumer preferences and buying behavior that inspires the creation of products that appeal to consumers at a mass scale. Committed to promoting wellbeing and quality of life through products it creates, the Company sees an opportunity in the infused beverages market as consumers seek new products that are aligned with a more health-conscious lifestyle. ReportLinker, an AI-driven market intelligence company, finds that the global cannabis beverages market is expected to reach US$2 billion by 2026. The US segment, where CBD-infused beverages are gaining popularity as they are becoming readily available through mainstream retail outlets, is estimated at US$649.1 million in 2021, accounting for a 70.9% share in the global market. According to the report, the changing legal status, growing societal acceptance, and increasing awareness of CBD benefits are attracting more and more food and drink companies to this burgeoning market as demand and sales grow (https://ibn.fm/pQCz9). With an innovation-focused approach, BevCanna itself employs an in-house brand and white label beverage manufacturing model in the cannabis beverage arena with distribution in regulated retail and online sales channels. Naturo Group (wholly owned subsidiary) employs an in-house brand and white label beverage manufacturing model in the CPG (traditional beverage + Natural product) arena with distribution in traditional retail and online sales. Pure Therapy (wholly owned subsidiary) employs a direct-to-consumer e-commerce model to sell natural health products, including nutraceutical and plant-based products across North America. With decades-long experience commercializing innovative products, the BevCanna team has a track record of developing highly customizable products, such as wellness and recreational beverages, that are targeted to various markets, including value, craft, and premium. Committed to building a lasting business and establishing dominance in the product category, BevCanna remains open to acquisitions, joint venture opportunities, and strategic partnerships. The Company appears confident that there exists a vast room for growth as consumers are just starting to explore opportunities within this dynamic product category. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• GreenBox POS is an advanced blockchain technology payment solutions provider focused on expanding its FinTech portfolio through strategic acquisitions in the United States and internationally
• The company acquired key assets during 2021 that demonstrate its commitment to expand its balance payment solutions for point-of-sale retail as well as e-commerce opportunities
• GreenBox announced this month that it has reached a binding agreement to acquire a licensed payment institution in the United Kingdom to further its debit and credit card payment processing abilities
• One of the company’s subsidiaries, ChargeSavvy, further highlighted the success of GreenBox’s strategy by announcing that it recorded a record 166 percent increase in its retail division’s book of business during the fourth quarter
• GreenBox has increased its funding options for repurchasing its common shares as a boon to shareholders and a display of the company’s confidence in its opportunities for 2022

Proprietary blockchain security and token technology-focused FinTech company GreenBox POS (NASDAQ: GBOX) is entering 2022 with expectations for another breakout year for customized payment solutions following successful bank and acquisition building campaigns during recent months. “Strategic acquisitions are already slated for 2022, so you all can expect to see a lot more of that in the year to come,” GreenBox’s Chief Operating Officer Vanessa Luna told investors during a corporate update call Dec. 9 (https://ibn.fm/fRMqX). “We’ll continue expanding our licensing and broadening our network and processing capabilities.” “Accumulating an array of technologies is vital to our long-term growth strategy, as GreenBox further progresses toward global expansion,” Chief Business Development Officer Pouya Moghavem stated. GreenBox’s July acquisition of point-of-sale company ChargeSavvy was GreenBox’s first major purchase that entailed an integration of the team, culture and operations of its new subsidiary, and the transaction granted ChargeSavvy a strong merchant client portfolio and point of sale technology, poising the division to grow into new categories where the same technology can be applied. Subsequently, ChargeSavvy recorded an average 166 percent increase YOY in its retail division’s book of business during the fourth quarter of 2021 — the best quarter in its nine-year history, according to the company (https://ibn.fm/mKQ3H). GreenBox is working to strengthening its standing with Visa and Signature Bank by establishing a well-balanced portfolio between point-of-sale retailers and e-commerce, onboarding low-risk merchants and eventually more high-margin clients, Luna and President of Global Payments Ken Haller told GreenBox’s investors during the December update call. That will in turn create opportunities for monetization through NFTs, card issuing, bank as a service, and blockchain closed loop systems. “Earlier in the year we purchased a payment processing company in Boston, allowing us to place merchant accounts on our own BIN. BIN is a high-level license in the U.S. that gives us great control and flexibility in onboarding merchants,” Haller said. Luna highlighted an exclusive joint venture in American Samoa that serves as a model market for FinTech payment solutions for island-type ecosystems around the world. As further evidence of GreenBox’s self-assurance in its growth strategy and pending opportunities, the company announced Jan. 6 a “substantial increase in the funds allocated for the immediate repurchase of the Company’s common shares, in the initial sum of $10M” (https://ibn.fm/V2drr). The company previously repurchased about 800,000 shares during the second half of 2021. For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX